imatinib is an orally administered tyrosine kinase inhibitor which inhibits the bcr-abl protein-tyrosine kinase with high selectivity. imatinib is rapidly absorbed from the gut, after oral intake and has an almost absolute bioavailability of 98%. the metabolism of imatinib is mediated by the cytochrome p450 (cyp) isoenzymes in the liver and gut wall. cgp74588 is a major active metabolite of ima...

Imatinib is an orally administered tyrosine kinase inhibitor which inhibits the Bcr-Abl protein-tyrosine kinase with high selectivity. Imatinib is rapidly absorbed from the gut, after oral intake and has an almost absolute bioavailability of 98%. The metabolism of imatinib is mediated by the cytochrome P450 (CYP) isoenzymes in the liver and gut wall. CGP74588 is a major active metabolite of ima...

mono-targeting by imatinib as a main antitumor agent does not always accomplish complete cancer suppression. 2,5-dimethyl-celecoxib (dmc) is a close structural analog of the selective cyclooxygenase-2 (cox-2) inhibitor, celecoxib, that lacks cox-2 inhibitory function. in this study, we aimed to show the apoptotic effects of imatinib in combination with dmc in human ht-29 colorectal cancer (crc)...

Background: Although Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML), not all patients reach complete remission and a considerable proportion of the patients develop resistance to Imatinib. Material and Methods: In an attempt to increase the tail on the survival curve, we conducted a Phase I/II study of PR1/BCR-ABL multipeptides vaccination trial in CML patients wit...

Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive CML patients. Methods: This study was done during 2013-2014, 20 new c...

Lipid nanocapsules (LNCs) represent a stable, biocompatible and worthwhile drug delivery system, demonstrating significant potential as gene/drug delivery platforms for cancer therapy. Imatinib, a potent tyrosine kinase inhibitor, has revolutionized the therapy of malignancies resulting from abnormal tyrosine kinase activity. However, its Clinical effectiveness in cancer treatment is h...

Lipid nanocapsules (LNCs) represent a stable, biocompatible and worthwhile drug delivery system, demonstrating significant potential as gene/drug delivery platforms for cancer therapy. Imatinib, a potent tyrosine kinase inhibitor, has revolutionized the therapy of malignancies resulting from abnormal tyrosine kinase activity. However, its Clinical effectiveness in cancer treatment is h...

Background: Imatinib, a tyrosine kinase inhibitor targeting bcr-abl, c-Kit, and PDGF receptors-alpha beta, is commonly used to treat GI stromal tumors hematologic malignancies. Hyperpigmentation known side-effect of imatinib, with intradermal hemosiderosis being the most common histologic finding.
 Case Presentation: We report rare case concurrent hypopigmentation hyperpigmentation seconda...

PEGylated polypropyleneimine (PPI) dendritic scaffold was used for the delivery of an anti-leukemic drug, Imatinib. The current study evolves and emerges the use PEGylated PPI dendritic scaffold for the delivery of this drug. In this Imatinib was synthesized and loaded with PEGylated PPI dendritic scaffold. Parameters such as FT-IR, NMR, SEM, drug release, DSC and hemolytictoxicity are required...

PEGylated polypropyleneimine (PPI) dendritic scaffold was used for the delivery of an anti-leukemic drug, Imatinib. The current study evolves and emerges the use PEGylated PPI dendritic scaffold for the delivery of this drug. In this Imatinib was synthesized and loaded with PEGylated PPI dendritic scaffold. Parameters such as FT-IR, NMR, SEM, drug release, DSC and hemolytictoxicity are required...